Browsing: Nordisks

“Mounjaro,” a popular obesity and type 2 diabetes treatment from US-based Eli Lilly, has received additional approval in the United States as a therapy that reduces the risk of cardiovascular diseases such as myocardial infarction and stroke. After Denmark’s Novo Nordisk secured cardiovascular protection indications for “Ozempic” and “Wegovy,” the competition between the two companies…

Novo Nordisk’s Weight-Loss Oral Drug Makes New Progress in China Approval | NAI 500

Novo Nordisk, a leading Danish pharmaceutical company, has embarked on a late-stage study to identify the minimal effective dose of its obesity drug, Wegovy. This strategic trial aims to retain market share in the competitive obesity sector, projected to be valued at over $100 billion annually by 2030

The Danish pharmaceutical giant is quietly advancing a fresh weapon in the obesity wars. Novo Nordisk has registered a first-in-human Phase I trial for an undisclosed weight-loss candidate, NNC0721-8060, which will be tested against its own blockbuster semaglutide — the active ingredient behind Wegovy and Ozempic — across 142 participants. The move signals that management…

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)